WALTHAM, Mass., May 20, 2019 PRNewswire — Corrona, LLC is pleased to announce a key milestone for the Corrona® Multiple Sclerosis (MS) Registry, a real-world US-based registry developed as a collaborative effort with the National MS Society. The collaborative registry model now includes Genentech, a member of the Roche Group, as the first pharmaceutical company to support and participate in the registry.
The Corrona MS Registry was created in 2017 to study the real-world effectiveness and safety of approved therapies for MS. Corrona’s sixth registry, the MS Registry collects high-quality clinical data prospectively from both MS patients and their treating neurologists. The registry has enrolled over 700 patients to date, and will serve as a reliable source of real-world insights on the comparative effectiveness and safety of MS therapies.
“The comprehensive, high-quality observational data generated by the registry will bridge the evidence gap in MS research and provide the real-world context needed to make informed treatment decisions,” said Dr. Bruce Bebo, Executive Vice President, Research of the National MS Society.
“The Corrona MS registry is uniquely positioned to help advance clinical research and improve patient care for the entire MS community, including both MS patients and their medical team,” said Dr. Daniel Kantor, Director of Neurology at Florida Atlantic University’s Schmidt College of Medicine and Scientific Co-Director for the registry.
Similar to Corrona’s other autoimmune disease registries, the MS registry collects detailed information about the patient journey including medication history and current treatments, comorbidities, clinical measures of effectiveness, adverse events, and patient reported outcomes.
“As a neurologist treating MS patients, reviewing data from an independent registry like Corrona can provide valuable insight into the impact of treatments on clinical outcomes and quality of life for MS patients,” said Dr. Aaron Miller, Professor of Neurology at Icahn School of Medicine at Mount Sinai and Scientific Co-Director for the registry.
In anticipation of the 21st Century Cures Act rapidly expanding the use of real-world observational data, Corrona has developed a collaborative model, working with multiple pharmaceutical companies to rapidly scale registries that benefit all stakeholders. “We envision that the collaborative registry model will continue to build momentum in the U.S., particularly for many autoimmune diseases where patient-reported outcomes and detailed clinical assessments remain the gold standard for studying real-world drug effectiveness,” said Dr. Jeff Greenberg, Chief Medical Officer of Corrona.
Learn more about the Corrona Multiple Sclerosis Registry and how to participate as a neurologist or a patient: visit https://www.corrona.org/registries/us-multiple-sclerosis-ms-registry
About Multiple Sclerosis
Multiple sclerosis is an unpredictable, often disabling immune-mediated disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to cognitive difficulties, visual loss and gait dysfunction. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.9 million people worldwide.
Corrona provides real-world evidence through syndicated registry data and analytics services, helping biopharmaceutical companies demonstrate the significant value and differentiation of their products to clinicians, patients, payers, and regulators. Corrona operates six major autoimmune registries across the USA, Canada, and Japan, collecting data from over 400 participating investigator sites. Corrona’s data are considered the gold standard in observational research, and has been used in over 140 per reviewed manuscripts and 430 abstracts. Corrona has conducted active safety surveillance to support regulatory commitments for 14 new drug approvals, including formal post authorization safety studies. Read more at www.corrona.org.
If you are interested in learning more about the Corrona MS Registry, please contact at email@example.com, (508) 408-5398. If you are interested in becoming a participating clinical site, please complete the brief online survey using the link below.
SOURCE Corrona, LLC